Zussanil-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying and gastroparesis. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing symptomatic relief from acid-related disorders including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of Domperidone and Esomeprazole in Zussanil-DSR Capsule offers comprehensive relief by addressing both motility dysfunction and acid hypersecretion. This combination is particularly beneficial in patients experiencing reflux symptoms accompanied by delayed gastric emptying. Zussanil-DSR Capsule should be used under medical supervision, with attention to contraindications such as known hypersensitivity to either component, and caution in patients with cardiac arrhythmias or electrolyte imbalances. Adherence to prescribed dosage and monitoring for potential side effects, including headache, dry mouth, or gastrointestinal disturbances, is recommended to ensure optimal therapeutic outcomes.